USFDA approves Sun Pharmaceutical's ANDA to market Rilutek tablets

Sun Pharmaceutical Industries Ltd. (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE:SUNPHARMA, BSE: 524715) announced that USFDA has granted a tentative approval for its Abbreviated New Drug Application (ANDA) to market a generic version of Sanofi Aventis's Rilutek® tablets 50 mg.

These generic Riluzole Hydrochloride tablets contain Riluzole Hydrochloride 50 mg. Riluzole Hydrochloride tablets are indicated in the treatment of amyotrophic lateral sclerosis.

Rilutek has annual sale of approximately $ 50 million in the US.

Source:

: Sun Pharmaceutical Industries Ltd.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Study shows how a single defective BRCA1 gene accelerates cancer development